<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208426</url>
  </required_header>
  <id_info>
    <org_study_id>201611053MINA</org_study_id>
    <nct_id>NCT03208426</nct_id>
  </id_info>
  <brief_title>Sequential Versus Quadruple Therapy in the Second-line Treatment</brief_title>
  <official_title>Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: A recent randomized trial showed that 14-day sequential therapy containing high
      dose proton pump inhibitor was higher than 95% in the first line treatment. However, whether
      the 14-day sequential therapy is more effective than 10-day bismuth quadruple therapy remains
      unknown. Therefore, the investigators aimed to compare the eradication rates and long term
      re-infection rates of sequential therapy for 14 days versus bismuth quadruple therapy for 10
      days in the second line treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, open labeled, randomized comparative trial Patients: 240
      patients with H. pylori infection who failed after first-line therapy will be eligible

      Interventions: eligible patients will be randomized into one of the two groups Group (A):
      sequential therapy for 14 days (S14)

      D1-D7: (esomeprazole 40mg bid + amoxicillin 1000mg bid) for 7 days

      D8-D14: (esomeprazole 40mg bid + clarithromycin 500mg bid + metronidazole 500mg bid) for
      another 7 days

      Group (B): bismuth quadruple therapy for 10 days (Q10)

      D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid +
      tetracycline 500mg qid) for 10 days

      Primary End Point: Eradication rate in the second line treatment according to intention to
      treat (ITT) analysis in the two treatment groups
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 10, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The technicians who performed the UBT test are blind to the treatment allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>eradication rate in the second-line treatment according to intention to treat (ITT) analysis</measure>
    <time_frame>6 weeks</time_frame>
    <description>Urea breath test will be performed at least 6 weeks after the end of eradication therapy. Successful eradication of H. pylori will be defined as a negative 13C-UBT result. A positive 13C-UBT test will be defined as a delta value of 4 units or greater. All subjects will be asked to stop PPI and H2-blocker for at least two weeks before 13C-UBT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects in the first line therapy in the two treatment groups</measure>
    <time_frame>2 weeks</time_frame>
    <description>At enrollment, the patients will be informed of the common side effects from the studied drugs and they will be asked to record these symptoms during treatment. A standardized interview and questionnaire will be used to assess the adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication rates in the second line treatment according to per protocol (PP) analysis</measure>
    <time_frame>6 weeks</time_frame>
    <description>Urea breath test will be performed at least 6 weeks after the end of eradication therapy. Patients not follow the protocol will be excluded for PP analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of gut microbiota in the two treatment groups</measure>
    <time_frame>2 weeks, 8 weeks, and 1 year</time_frame>
    <description>the stool specimens before, 2weeks after, 8 weeks after, and 1 year after the treatment will be collected for gut microbiota analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-infection rate one year after eradication therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Urea breath test will be performed 1 year after the end of eradication therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Sequential therapy for 14 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential therapy for 14 days (experimental) D1-D7: (Nexium, esomeprazole 40mg bid + amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid) for 7 days D8-D14: (Nexium, esomeprazole 40mg bid + Klaricid XL, clarithromycin 500mg bid + Flagyl, metronidazole 500mg bid) for another 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bismuth quadruple therapy for 10 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bismuth quadruple therapy for 10 days (active comparator) D1-D10: (Nexium, esomeprazole 40mg bid + KCB F.C. TABLETS, dibismuth trioxide 120mg qid + Flagyl, metronidazole 500mg tid + tetracycline (Brand name: Tetracycline Capsule ) 500mg qid) for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole (S14)</intervention_name>
    <description>Nexium, esomeprazole 40mg bid, 14 days</description>
    <arm_group_label>Sequential therapy for 14 days</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole (BQ10)</intervention_name>
    <description>Nexium, esomeprazole, 40mg bid for 10 days</description>
    <arm_group_label>bismuth quadruple therapy for 10 days</arm_group_label>
    <other_name>Nexium (BQ10)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin (ST14)</intervention_name>
    <description>Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days</description>
    <arm_group_label>Sequential therapy for 14 days</arm_group_label>
    <other_name>amoxicillin capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin (ST14)</intervention_name>
    <description>Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)</description>
    <arm_group_label>Sequential therapy for 14 days</arm_group_label>
    <other_name>Klaricid-XL 500mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole (ST14)</intervention_name>
    <description>Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)</description>
    <arm_group_label>Sequential therapy for 14 days</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dibismuth trioxide 120mg (BQ10)</intervention_name>
    <description>KCB F.C. TABLETS, dibismuth trioxide 120mg qid for 10 days</description>
    <arm_group_label>bismuth quadruple therapy for 10 days</arm_group_label>
    <other_name>KCB F.C. TABLETS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole (BQ10)</intervention_name>
    <description>Flagyl, metronidazole 500mg tid for 10 days</description>
    <arm_group_label>bismuth quadruple therapy for 10 days</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracycline (BQ10)</intervention_name>
    <description>Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days</description>
    <arm_group_label>bismuth quadruple therapy for 10 days</arm_group_label>
    <other_name>Tetracycline Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  H. pylori infected patients who fail from first line standard triple therapy with
             clarithromycin, amoxicillin, and a proton pump inhibitor will be eligible in this
             study.

        Exclusion Criteria:

        Patients will be excluded from the study if any one of the following criteria was present:

          -  children and teenagers aged less than 20 years,

          -  history of gastrectomy,

          -  gastric malignancy, including adenocarcinoma and lymphoma,

          -  previous allergic reaction to antibiotics (bismuth, metronidazole, levofloxacin,
             tetracycline) and PPI (esomeprazole),

          -  contraindication to treatment drugs,

          -  pregnant or lactating women,

          -  severe concurrent disease, or

          -  Unwilling to accept random assignment of subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>63541</phone_ext>
    <email>jyhmingliou@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming-Shiang Wu</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65043</phone_ext>
    <email>mingshiang@ntu.edu.tw</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18.</citation>
    <PMID>27769562</PMID>
  </results_reference>
  <results_reference>
    <citation>Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013 Jan 19;381(9862):205-13. doi: 10.1016/S0140-6736(12)61579-7. Epub 2012 Nov 16. Erratum in: Lancet. 2013 Apr 13;381(9874):1276.</citation>
    <PMID>23158886</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efficacy, Self</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

